Your partner for dermatological trials — trusted, proven, and precise
Sponsors rely on Biorasi’s experience across common and rare skin conditions — backed by responsive teams, integrated platforms, and real-world delivery.
WHY BIORASI FOR DERMATOLOGY?
From pediatric plaque psoriasis to adult rosacea and microbiome therapies, Biorasi brings discipline to every dermatology protocol. Our role is not just execution — safeguarding trial integrity and meeting sponsor timelines while fostering trust across investigators, sites, and regulators.
Subspecialties
- Rosacea
- Atopic Dermatitis
- Plaque Psoriasis
- Pediatric Dermatology
- Rare Skin Disorders
- Skin Microbiome-Based Therapies
Proof of
Performance
- 25 Studies
- 16 Indications
- 6,510 Patients Enrolled
Case Studies and Results
- Rapid & Time-Sensitive Execution in Rosacea
- Enrolled 140 patients at 8 sites in 4 months
- Achieved a 4% dropout rate (vs. expected 19%)
- Topline results delivered 7 days ahead of schedule
- Demonstrated controlled execution in a crowded market
FROM OUR PARTNERS
Hyun Kim
VP Clinical Operations, AOBiome Therapeutics
I cannot think of anyone else to work with other than Biorasi
Our relationship is not just a Sponsor-CRO relationship. It is really a true partnership.
Supriya Lala Kundu
Research Analyst, Best Practices, Frost & Sullivan
Biorasi provides the necessary framework, capability, scalability, and flexibility for protocol design and enhancement as per the evolving regulatory environment, early in the clinical trial process, to seamlessly progress the trial. An expert in digital therapeutic trials, the company flexibly manages the trial complexity, clinical validation, regulatory approval, and payer reimbursement.
Amy Beasley
Former Manager of Clinical Operations, Savara Pharmaceuticals
Biorasi far exceeds other vendors.
“For flexibility, nimbleness, and willingness to partner with us to solve our problems, Biorasi far exceeds other vendors. They give attention and detail to smaller-sized companies like us, and provide a great strategic value.”
Mary Varhgese Presti
Vice President, Life Sciences, IBM Watson Health
Biorasi and IBM Health: Greater Efficiency and Precision
Biorasi has been at the forefront of e-clinical innovation and has demonstrated continued leadership in leveraging the ICD platform. We are proud to support Biorasi’s ongoing effort to bring greater efficiency and precision to the clinical trial process, particularly in emerging areas such as digital therapeutics, virtual trials, and precision medicine.
FROM THE LIBRARY
Article
Aiming Higher in Dermatology Clinical Trials
Article
Biorasi Meets First Patient, First Visit Milestone for Dermatology Trial During COVID-19
Article
Biorasi Welcomes Dermatologist Dr. Lawrence Green to Scientific Advisory Board
Case Study